Patients with mild acne vulgaris (defined by IGA 1 and 2) Acne vulgaris, skin microbiome, La Roche-Posay Effaclar duo plus, VAA cream, Benzoyl peroxide
Conditions
Interventions
La Roche-Posay Effaclar duo plus group:
Subjects will be instructed to apply 1 fingertip of La Roche-Posay Effaclar duo plus(equivalent to 2.5 grams) in the morning and evening to their entire face af
Experimental Other,Active Comparator Drug,Active Comparator Drug
La Roche-Posay Effaclar duo plus,VAA 0.025% cream,Benzoyl peroxide 2.5% gel
Sponsors
L'Oreal Thailand
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Men or women with 18-45 years old at the time of screening 2. Presence of minimum of 10 comedones and maximum of 5 inflammatory acne on the face 3. Mild acne vulgaris defined as IGA 1 (Almost clear; rare noninflammatory lesions with more than one small inflammatory lesion) to IGA 2 (Mild severity; some inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions) 4. Subjects who are willing to use nonantibacterial bar soap for facial cleansing throughout the study 5. Subjects who are informed in detail about the research study and express their interests in participation. 6. Subjects must be able to comply with study protocol
Exclusion criteria
Exclusion criteria: 1. History of systemic or topical antibiotic use within 1 month prior to the baseline study visit 2. Dermatologic procedural treatments within previous 6 months before study enrollment 3. Systemic acne treatment within 4 weeks before study enrollment. 4. Topical acne treatment within 2 weeks before study enrollment. 5. Female subjects who have significant signs of hyperandrogenism or history of irregular menstrual cycles 6. Female subjects who are currently in pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alteration in facial microbiome profiles(changes in proliferation and diversity of facial microbiota) in each arm of treatment baseline, 1st and 3rd month 16s rRNA sequencing from facial swabs,Reduction on acne lesion count baseline, 1st month and 3rd month Acne lesion count was performed by counting of each different types of acne (closed comedones, open comedones, inflammatory papules, pustules) on each designated area of the face | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects 1st and 3rd month Adverse effects such as active dermatitis, redness, edema, dryness will be graded by 4-point grading scores,Subject's satisfaction 3rd month Satisfaction is evaluated by VAS score | — |
Countries
Thailand
Contacts
Public ContactChanat Kumtornrut
Division of Dermatology, Faculty of Medicine, Chulalongkorn university
Outcome results
None listed